Liposomal Bupivacaine for Post-Cesarean Pain

Overseen By Antonio Gonzalez, MD

Age: 18 - 65

Sex: Female

Trial Phase: Phase 4

Sponsor: Yale University

Disqualifiers: Magnesium sulfate, NICU admission, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

Duration: Immediate post-operative period

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to manage pain after a cesarean delivery using liposomal bupivacaine, a drug designed for long-lasting pain relief. The study compares three treatment approaches: standard bupivacaine, bupivacaine with steroids (anti-inflammatory drugs), and liposomal bupivacaine. The goal is to determine if liposomal bupivacaine can reduce the need for opioids (strong painkillers) for up to 72 hours after surgery. Ideal participants are pregnant individuals planning a cesarean delivery, without allergies to the trial drugs, and who have not recently or chronically used opioids. As a Phase 4 trial, this research involves an FDA-approved treatment, aiming to understand its benefits for more patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, if you are using opioids, you may not be eligible to participate.

What is the safety track record for these treatments?

Research has shown that liposomal bupivacaine can reduce the need for opioids for up to 72 hours after a C-section, longer than regular bupivacaine. It releases slowly over time, controlling pain with just one dose during surgery.

Studies have also examined bupivacaine combined with dexamethasone and methylprednisolone for spinal anesthesia during C-sections. These combinations are generally well-tolerated and help manage post-surgery pain.

Both liposomal bupivacaine and the steroid combinations (such as dexamethasone and methylprednisolone) have been well-studied. They are safe for managing pain after a C-section, potentially reducing the need for opioids, which benefits many patients. ^{1 2 3 4 5}

Why are researchers enthusiastic about this study treatment?

Researchers are excited about liposomal bupivacaine for post-cesarean pain because it offers a novel delivery method that extends pain relief. Unlike traditional bupivacaine, which typically provides relief for a shorter duration, liposomal bupivacaine slowly releases the active ingredient over time, potentially reducing the need for additional pain medications. This could lead to more consistent pain management and a better recovery experience for new mothers.

What evidence suggests that this trial's treatments could be effective for post-cesarean pain?

In this trial, participants will receive different treatments to manage post-cesarean pain. Research has shown that liposomal bupivacaine, administered to participants in one arm of this trial, can significantly reduce the need for opioids for up to 72 hours after a cesarean delivery. Its slow-release design provides longer-lasting pain relief from a single dose. Another arm of the trial will use traditional bupivacaine combined with the steroids dexamethasone and methylprednisolone, which can extend pain relief by about 7 hours compared to bupivacaine alone. These steroids help reduce inflammation and pain. Overall, both treatments show promise for managing pain after a cesarean, potentially reducing the need for additional pain medications. ^{6 7 8 9 10}

Who Is on the Research Team?

Antonio Gonzalez, MD

Principal Investigator

Yale University

Are You a Good Fit for This Trial?

This trial is for women aged 18-45 undergoing cesarean delivery without allergies to morphine or bupivacaine, no anxiety history, and no recent/chronic opioid use. They should be generally healthy (ASA-1 to ASA-3). Overweight individuals (BMI > 45), those needing magnesium sulfate therapy, additional surgeries beyond cesarean or whose newborns require intensive care are excluded.

Inclusion Criteria

I have not used opioids recently or regularly.

You are not allergic to bupivacaine.

You are not allergic to morphine.

Exclusion Criteria

I need surgery beyond a C-section and possibly tying my tubes.

I need Magnesium sulfate treatment.

My BMI is over 45.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive spinal anesthesia and a TAP block with either liposomal bupivacaine, bupivacaine, or a control procedure during cesarean delivery

Immediate post-operative period

1 visit (in-person)

Post-operative Monitoring

Participants are monitored for pain management and recovery using ObsQoR-11 surveys and step counts

72 hours

Continuous monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Bupivacaine
• Dexamethasone and Methylprednisolone
• Liposomal Bupivacaine
• TAP Block

Trial Overview The study tests the effectiveness of a TAP block using Liposomal Bupivacaine (LB) versus standard Bupivacaine and steroids for post-cesarean pain relief. It aims to reduce opioid use by providing prolonged pain control with LB compared to short-term effects seen with traditional methods.

How Is the Trial Designed?

Group I: Liposomal Bupivacaine Experimental Treatment 2 Interventions

Patient will receive intrathecal morphine + TAP block with Liposomal bupivacaine and bupivacaine 0.25%

Group II: Control group (Bupivacaine) Active Control 1 Intervention

Patient will receive intrathecal morphine and TAP block with plain bupivacaine.

Group III: Bupivacaine + dexamethasone and methylprednisolone Active Control 1 Intervention

Patient will receive intrathecal morphine + TAP block with only bupivacaine.

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials

1,963

Recruited

3,046,000+

Published Research Related to This Trial

In a study of 186 women undergoing cesarean delivery, the use of a transversus abdominis plane (TAP) block with long-acting liposomal bupivacaine (LB) plus bupivacaine HCl significantly reduced total opioid consumption compared to bupivacaine HCl alone, with a mean difference of -16.5 mg over 72 hours.

The addition of LB did not increase pain intensity compared to bupivacaine HCl alone, supporting its efficacy in reducing opioid use without compromising pain management, although a slightly higher percentage of patients experienced adverse events in the LB group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Transversus Abdominis Plane Block With Liposomal Bupivacaine for Pain After Cesarean Delivery in a Multicenter, Randomized, Double-Blind, Controlled Trial. Nedeljkovic, SS., Kett, A., Vallejo, MC., et al.[2022]

In a study of 76 patients undergoing outpatient arthroscopic rotator cuff repair, liposomal bupivacaine (LB) significantly reduced postoperative narcotic consumption compared to conventional bupivacaine combined with dexamethasone, indicating its effectiveness in pain management.

Both LB and LB combined with dexamethasone showed similar outcomes in narcotic use, suggesting that LB alone is sufficient for effective pain control, which can help decrease reliance on narcotics after surgery.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Single-Shot Liposomal Bupivacaine Reduces Postoperative Narcotic Use Following Outpatient Rotator Cuff Repair: A Prospective, Double-Blinded, Randomized Controlled Trial. Baessler, AM., Moor, M., Conrad, DJ., et al.[2021]

In a study of 58 patients undergoing cesarean sections, adding 8 mg of perineural dexamethasone to bupivacaine during a TAP block significantly prolonged the time to first request for pain relief medication to 8.5 hours compared to 5.3 hours for bupivacaine alone.

Patients receiving dexamethasone also reported lower pain intensity scores at 6, 12, and 24 hours post-surgery and required less total analgesic medication over 24 hours, indicating improved pain management without adverse effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The use of perineural dexamethasone and transverse abdominal plane block for postoperative analgesia in cesarean section operations under spinal anesthesia: an observational study. Aga, A., Abrar, M., Ashebir, Z., et al.[2022]

In a study involving patients undergoing robot-assisted hysterectomy, the use of liposomal bupivacaine in subcostal TAP blocks significantly reduced total opioid use in the first 72 hours post-surgery compared to standard bupivacaine.

Patients receiving liposomal bupivacaine reported lower maximum pain scores and had a decreased incidence of nausea and vomiting, suggesting improved overall satisfaction and comfort after surgery.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: A prospective randomized controlled study. Hutchins, J., Delaney, D., Vogel, RI., et al.[2022]

Incorporating dexamethasone into bupivacaine-loaded microspheres significantly prolongs the duration of motor block, making it a promising enhancement for pain management in clinical settings.

While dexamethasone alone does not cause motor block, its addition to bupivacaine can delay the onset of motor block without affecting the drug's pharmacokinetics, suggesting a complex interaction that could optimize anesthesia outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effect of dexamethasone on motor brachial plexus block with bupivacaine and with bupivacaine-loaded microspheres in a sheep model. Estebe, JP., Le Corre, P., Clément, R., et al.[2019]

A review of 76 randomized controlled trials found that only 11% showed a significant benefit of liposomal bupivacaine over standard bupivacaine or ropivacaine for postoperative pain control.

The majority of trials indicated that unencapsulated bupivacaine provided better pain relief than liposomal bupivacaine, suggesting that routine use of liposomal bupivacaine may not be justified based on current evidence.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical Effectiveness of Liposomal Bupivacaine Administered by Infiltration or Peripheral Nerve Block to Treat Postoperative Pain. Ilfeld, BM., Eisenach, JC., Gabriel, RA.[2021]

Liposomal bupivacaine (LB) used in a transversus abdominis plane (TAP) block, either alone or with intrathecal morphine (ITM), resulted in similar opioid consumption compared to ITM alone for pain management after cesarean delivery, indicating its effectiveness as an analgesic option.

Both LB groups experienced significantly less pruritus (itchiness) compared to the ITM group, suggesting that LB may offer a safer profile with fewer side effects in postoperative pain management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Randomized trial of transversus abdominis plane block with liposomal bupivacaine after cesarean delivery with or without intrathecal morphine. Habib, AS., Nedeljkovic, SS., Horn, JL., et al.[2022]

In a study of 60 patients undergoing donor nephrectomy, subcostal TAP blocks using liposomal bupivacaine resulted in significantly lower maximal pain scores compared to non-liposomal bupivacaine at 24-72 hours post-injection.

Patients receiving liposomal bupivacaine also required less opioid medication (fentanyl) in the 48-72 hour period after surgery, indicating better pain management with liposomal bupivacaine.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ultrasound-guided subcostal transversus abdominis plane blocks with liposomal bupivacaine vs. non-liposomal bupivacaine for postoperative pain control after laparoscopic hand-assisted donor nephrectomy: a prospective randomised observer-blinded study. Hutchins, JL., Kesha, R., Blanco, F., et al.[2022]

In a study involving 60 patients undergoing abdominal surgery, adding dexamethasone to bupivacaine for a TAP block significantly reduced postoperative pain at 2, 4, and 12 hours compared to bupivacaine alone.

The combination of dexamethasone and bupivacaine not only prolonged the time to first analgesia but also resulted in lower morphine consumption and reduced nausea and vomiting, indicating a safer and more effective pain management strategy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effect of adding dexamethasone to bupivacaine on transversus abdominis plane block for abdominal hysterectomy: A prospective randomized controlled trial. Ammar, AS., Mahmoud, KM.[2022]

In a study of 287 patients undergoing colorectal surgery, the timing of transversus abdominis plane (TAP) blocks with liposomal bupivacaine (before or after anesthesia induction) did not significantly affect postoperative pain scores or opioid consumption.

However, patients who received TAP blocks after surgery required more ketorolac, indicating that while timing may not impact pain control, it could influence the use of additional non-opioid analgesics.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Timing of Transversus Abdominis Plane Block and Postoperative Pain Management. Escudero-Fung, M., Lehman, EB., Karamchandani, K.[2022]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC4076920/

The effect of intravenous Dexamethasone on post ... IV Dexamethasone could efficiently reduce post-operative pain severity and the need for analgesic consumption and improve vital signs after cesarean section.

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12339520/

Effect of varying doses of dexmedetomidine added to ... This study investigates the impact of different doses of dexmedetomidine combined with dexamethasone as an adjunct to transversus abdominis ...

3. healthcare-bulletin.co.uk healthcare-bulletin.co.uk/article/comprehensive-comparison-of-bupivacaine-alone-versus-bupivacaine-plus-dexamethasone-in-transverse-abdominis-plane-block-for-optimizing-postoperative-analgesia-in-cesarean-deliveries-a-randomized-controlled-study-4310/

Comprehensive Comparison of Bupivacaine Alone Versus ... Results The addition of Dexamethasone to Bupivacaine significantly extended the duration of postoperative analgesia by approximately 7 hours compared to ...

4. sciencedirect.com sciencedirect.com/science/article/pii/S0952818023003033

High dose glucocorticoids for treatment of postoperative pain Doses ranging from 0.05 to 0.1 mg/kg of dexamethasone and 40 mg of methylprednisolone have been proven to be highly effective in prevention and treatment of ...

5. cureus.com cureus.com/articles/119249-comparison-of-dexamethasone-versus-methylprednisolone-with-bupivacaine-in-transversus-abdominis-plane-block-for-attenuation-of-chronic-postoperative-abdominal-pain.pdf

Comparison of Dexamethasone Versus ... Patients with persistent postoperative abdominal pain receiving bupivacaine and methylprednisolone in an ultrasonography-guided TAP block ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11246683/

Intrathecal dexamethasone-bupivacaine combination with ... The study investigated the effect of intrathecal dexamethasone-bupivacaine combination with bupivacaine alone in spinal anesthesia for cesarean delivery.

7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10654453/

Comparison of Dexamethasone Versus Methylprednisolone ... In this study, the effects of bupivacaine and corticosteroids, particularly dexamethasone and methylprednisolone, on chronic abdominal pain following surgery ...

8. researchgate.net researchgate.net/publication/6841943_Effects_of_Perioperatively_Administered_Bupivacaine_and_Bupivacaine-Methylprednisolone_on_Pain_after_Lumbar_Discectomy

Effects of Perioperatively Administered Bupivacaine and ... In addition, our data suggest that preemptive infiltration of the wound site with bupivacaine alone provides similar pain control to preemptive ...

9. asahq.org asahq.org/standards-and-practice-parameters/statement-on-the-use-of-adjuvant-medications-and-management-of-intraoperative-pain-during-cesarean-delivery

Statement on the Use of Adjuvant Medications and ... This statement serves to inform practitioners and give recommendations that may help decrease pain during cesarean delivery under neuraxial anesthesia.

10. ashp.org ashp.org/-/media/assets/policy-guidelines/docs/endorsed-documents/endorsed-documents-fourth-consensus-guidelines-postop-nausea-vomiting.pdf

Fourth Consensus Guidelines for the Management of ... This consensus statement presents a comprehensive and evidence-based set of guidelines for the care of postoperative nausea and vomiting ...